Experience real-time quotes &

news with the most powerful

iPhone application for investors.

Get the FREE DailyFinance iPhone application



  • SYNTA PHARMACEUTICALS CORP Analyst Recommendations

  • Analyst Consensus: SNTA

    First Call Consensus Recommendation

    • Strong Buy1
    • Buy2
    • Hold3
    • Sell4
    • Strong Sell5
    Mean Analyst Consensus Recommendation Analysts Reporting
    Current Recommendation 3.200 Hold 5
    30 Days Ago 3.400 Hold 5
    60 Days Ago 3.400 Hold 5
    90 Days Ago 3.400 Hold 5
    120 Days Ago 3.500 Underperform 4

  • Analyst Ratings: SNTA

    Brokerage Firm Previous Rating Current Rating Change Date Price Target
    Roth Capital Hold Buy 11/05/2009 4.00
    RBC Capital Mkts Outperform Sector Perform 02/27/2009 —
    Rodman & Renshaw Mkt Outperform Mkt Perform 02/27/2009 —
    Lazard Capital Buy Hold 02/27/2009 —
    Wachovia Mkt Perform Underperform 02/27/2009 —
    Roth Capital Buy Hold 02/26/2009 2.00
    Banc of America Sec — Neutral 12/01/2008 —
    Rodman & Renshaw — Mkt Outperform 11/20/2008 —
    Wachovia — Mkt Perform 11/06/2008 —
    Friedman Billings Outperform — 07/10/2008 —
    Friedman Billings Outperform — 06/30/2008 —
    Susquehanna Financial — Positive 06/02/2008 16.00
    Roth Capital — Buy 04/09/2008 11.00
    Friedman Billings — Outperform 03/12/2008 13.00
    RBC Capital Mkts — Outperform 01/31/2008 —
    Rodman & Renshaw — Mkt Outperform 10/11/2007 18.00
    Rodman & Renshaw — Mkt Outperform 10/02/2007 16.00
    Lazard Capital — Buy 03/19/2007 12.00
    Bear Stearns — Outperform 03/19/2007 14.00
    Lehman Brothers — Equal-weight 03/19/2007 —